Eurasian Health Journal
ISSN 1694-8882 / e-ISSN 1694-8890
Submit an article
Vol. 17, No. 4, 2025 / Pages 256-270

Health status and clinical characteristics of patients with haemophilia in the Kyrgyz Republic

Nazgul Zhaparova Erbol Sadabaev Oromnbek Dzjakypbaev Muhametalim Tursunbekov Sagynali Mamatov Timur Narbekov
Received 17.07.2025
Revised 18.11.2025
Accepted 25.12.2025

Abstract

Haemophilia is an X-linked inherited bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) in haemophilia A or factor IX (FIX) in haemophilia B. This study aimed to examine the demographic profile, health status and clinical characteristics of patients with haemophilia A and B in the Kyrgyz Republic. A total of 81 patients with haemophilia were enrolled, including 70 with haemophilia A and 11 with haemophilia B. Data collected comprised age, educational level, FVIII/FIX activity levels, the presence of anti-FVIII/FIX inhibitors, treatment regimen, viral infections and annual bleeding rate. In addition, the translated and validated version of the Haemophilia Quality of Life Questionnaire for Adults (Haem-QoL-A) and the Haemophilia Joint Health Score (HJHS) were used. Factor VIII inhibitors were identified in four patients, while one patient had factor IX inhibitors. No patient in the study cohort received prophylactic therapy; however, inadequate on-demand treatment was reported. With regard to viral infections, nine patients (11.1%) were found to have transfusion-transmitted viruses. The median annual bleeding rate was 23 bleeding episodes per year (range 2-49). The mean Haem-QoL-A score was 54.26 ± 18.73. The average total haemophilia joint health score for adult patients with haemophilia A/haemophilia B was 39.2 ± 18.7 (p < 0.05). There are significant problems for adult patients with haemophilia in the Kyrgyz Republic, such as insufficient treatment and the lack of prophylaxis. To solve these problems, it is necessary to develop a strategy for improving the health care system, training health care professionals and providing sustainable funding

Keywords

haemophilia; coagulation factors VIII and IX; health status; clinical characteristics

Suggested citation

APA Style
Zhaparova, N., Sadabaev, E., Dzjakypbaev, O., Tursunbekov, M., Mamatov, S. & Narbekov, T. (2025). Health status and clinical characteristics of patients with haemophilia in the Kyrgyz Republic. Eurasian Health Journal, 17(4), 256-270. https://doi.org/10.54890/1694-8882-2025-4-256
Copied!
Vancouver Style
Zhaparova, N., Sadabaev, E., Dzjakypbaev, O., Tursunbekov, M., Mamatov, S., Narbekov, T.. Health status and clinical characteristics of patients with haemophilia in the Kyrgyz Republic. Eurasian Health J. 2025;17(4):256-70. https://doi.org/10.54890/1694-8882-2025-4-256
Copied!

References

  1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–e47. DOI: 10.1111/j.1365-2516.2012.02909.x
  2. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: Diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–97. DOI: 10.1016/S0140-6736(15)01123-X
  3. Mannucci PM, Tuddenham EGD. The hemophilias – from royal genes to gene therapy. N Engl J Med. 2001;344:1773–9. DOI: 10.1056/NEJM200106073442307
  4. Lee CA, Kessler CM, Varon D, Martinowitz U, Heim M, Aledort LM. Unsolved problems in haemophilia. Haemophilia. 1998;4(4):341–5.
  5. Lee CA, Kessler CM, Varon D, Martinowitz U, Heim M. Towards achieving global haemophilia care – World Federation of Hemophilia programmes. Haemophilia. 1998;4(4):463–73. DOI: 10.1046/j.1365-2516.1998. 440463.x
  6. Stonebraker JS, Brooker M, Amand RE, Farrugia A, Srivastava A. A study of reported factor VIII use around the world. Haemophilia. 2010;16(1):33–46. DOI: 10.1111/j.1365-2516.2009.02131.x
  7. Chuansumrit A, Ruchutrakul T, Sirachainan N, Kitpoka P, Panuwannakorn M, Panburana P, et al. National strategic advocacy to manage patients with inherited bleeding disorders in low and lower-middle income countries. Expert Rev Hematol. 2023;16(12):1063–76. DOI: 10.1080/17474086.2023.2293092
  8. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(56):1–158. DOI:10.1111/hae.14046
  9. Lindvall K, Von Mackensen S, Berntorp E. Quality of life in adult patients with haemophilia – a single centre experience from Sweden. Haemophilia. 2012;18(4):527–31. DOI: 10.1111/j.1365-2516.2012.02765.x
  10. Payal V, Sharma P, Goyal V, Jora R, Parakh M, Payal D. Clinical profile of hemophilia patients in Jodhpur Region. Asian J Transfus Sci. 2016;10(1):101–4. DOI: 10.4103/0973-6247.164269
  11. Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, et al. Haemophilia. Nat Rev Dis Primers. 2021;7:45. DOI: 10.1038/s41572-021-00278-x
  12. Roosendaal G, Jansen NWD, Schutgens R, Lafeber FPJG. Haemophilic arthropathy: The importance of the earliest haemarthroses and consequences for treatment. Haemophilia. 2008;14(6):4–10. DOI: 10.1111/j.13652516.2008.01882.x
  13. Daffunchio C, Galatro G, Rossi M, Landro M, Andreu M, Neme D, et al. Clinical and ultrasound evaluation of patients with haemophilia on prophylaxis. Haemophilia. 2021;27(4):641–7. DOI: 10.1111/hae.14312
  14. Islam MN, Biswas AR, Nazneen H, Chowdhury N, Alam M, Banik J, et al. Clinical profile and demographic characteristics of moderate and severe hemophilia patients in a tertiary care hospital of Bangladesh. Orphanet J Rare Dis. 2022;17(1):254. DOI: 10.1186/s13023-022-02413-7
  15. Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM. Men with severe hemophilia in the United States: Birth cohort analysis of a large national database. Blood. 2016;127(24):3073–81. DOI: 10.1182/ blood-2015-10-675140
  16. Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: A meta-analysis. J Antimicrob Chemother. 2008;61(6):1191–200. DOI: 10.1093/jac/dkn119
  17. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood. 2008;112(7):2617–26. DOI: 10.1182/blood-2008-07-077370
  18. Van Velzen AS, Eckhardt CL, Peters M, Leebeek FWG, Escuriola-Ettingshausen C, Hermans C, et al. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: Results of the INSIGHT case-control study. J Thromb Haemost. 2017;15(7):1422–29. DOI: 10.1111/jth.13711
  19. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054–64. DOI: 10.1056/ NEJMoa1516437
  20. Giangrande PLF, Hermans C, O’Mahony B, de Kleijn P, Bedford M, Batorova A, et al. European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis. 2018;13:66. DOI: 10.1186/s13023018-0800-z
  21. Eshghi P, Mahdavi-Mazdeh M, Karimi M, Aghighi M. Haemophilia in the developing countries: the Iranian experience. Arch Med Sci. 2010;6(1):83-89. DOI: 10.5114/aoms.2010.13512
  22. Skinner MW, Nugent D, Wilton P, O’Mahony B, Dolan G, O’Hara J, et al. Achieving the unimaginable: Health equity in haemophilia. Haemophilia. 2020;26(1):17–24. DOI: 10.1111/hae.13862
  23. Jones P, Robillard L. The World Federation of Hemophilia: 40 years of improving haemophilia care worldwide. Haemophilia. 2003;9(6):663–9. DOI: 10.1046/j.1351-8216.2003.00831.x
  24. Wilkins RA, Siddle HJ, Chapman GJ, Horn E, Walwyn R, Redmond AC. The impact of ankle haemarthropathy in patients with moderate haemophilia. Haemophilia. 2023;29(2):600–7. DOI: 10.1111/hae.14720
  25. O’Hara S, Castro FA, Black J, Chaplin S, Ruiz L, Hampton RJ, et al. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia. 2021;27(1):113–9. DOI: 10.1111/hae.14171
  26. Zorenko VY, Makhmudova AD, Schiller EE, Polyanskaya TY, Berger IV, Juraeva NT, et al. First modern Russian plasma-derived coagulation factor VIII concentrate (Eytoplasm): Results of clinical study of pharmacokinetics, efficacy and safety. Russ J Hematol Transfusiol. 2024;69(4):451–62. DOI: 10.35754/0234-5730-2024-69-4451-462